ACTINOGEN MEDICAL LTD

Actinogen Medical’s latest AGM shows strong governance and a new placement facility while its shares slide amid broader biotech volatility.

Actinogen Medical’s share jump follows a Phase 2b/3 Alzheimer’s trial lock‑in, sparking optimism yet highlighting the need for clearer results before valuing its stock.

Actinogen Medical’s database lock on its XanaMIA Phase 2b/3 trial narrows the next topline to mid‑November, cutting uncertainty and setting a clear investor milestone.